RATIO-VALPROIC 50MG/ML SYRUP 50 MG
VALPROIC ACID (SODIUM VALPROATE) : 50 MG · DIN 02140063 · RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is RATIO-VALPROIC 50MG/ML SYRUP?
RATIO-VALPROIC 50MG/ML SYRUP 50 MG contains VALPROIC ACID (SODIUM VALPROATE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02140063, held by RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED, supplied as SYRUP for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 26-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RATIO-VALPROIC 50MG/ML SYRUP used for?
Sole or adjunctive therapy for simple or complex absence seizures (petit mal); adjunctive therapy for multiple seizure types including absence or tonic-clonic seizures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02140063 |
|---|---|
| Brand name | RATIO-VALPROIC 50MG/ML SYRUP |
| Generic / active ingredient | VALPROIC ACID (SODIUM VALPROATE) : 50 MG |
| Manufacturer | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED |
| Strength | 50 MG |
| Dosage form | SYRUP |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N03AG01 VALPROIC ACID |
| AHFS class | 28:12.92 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 26-Oct-2015 |
| Original market date | 1998-01-19 00:00:00 |
How is it administered?
Dosage should be titrated to and maintained at the lowest dose consistent with optimal seizure control. Use with extreme caution as a sole agent in children under 2 years.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to STORAGE AND STABILITY section).
How is it supplied?
Not explicitly detailed in provided text (refers to DOSAGE FORMS, COMPOSITION AND PACKAGING section).
Contraindications
Hepatic disease or significant hepatic dysfunction; known hypersensitivity to the drug; known urea cycle disorders.
Warnings and precautions
Serious/fatal hepatotoxicity (especially first 6 months); life-threatening pancreatitis; suicidal ideation/behaviour; multi-organ hypersensitivity; serious skin reactions with lamotrigine.
What can be used instead?
Other Canadian products sharing ATC code N03AG01 VALPROIC ACID. 17 of 70 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-DIVALPROEX | 125 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239698 |
| APO-DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239699 |
| APO-DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | MARKETED | DIN 02239700 |
| APO-VALPROIC ACID | 250 MG | CAPSULE | APOTEX INC | MARKETED | DIN 02238048 |
| DEPAKENE | 250 MG / 5 ML | SOLUTION | BGP PHARMA ULC | MARKETED | DIN 00443832 |
| EPIVAL | 125 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596418 |
| EPIVAL | 250 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596426 |
| EPIVAL | 500 MG | TABLET (DELAYED-RELEASE) | BGP PHARMA ULC | MARKETED | DIN 00596434 |
| JAMP DIVALPROEX | 250 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02551152 |
| JAMP DIVALPROEX | 500 MG | TABLET (DELAYED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02551160 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.